Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA has approved RHA Redensity Eye, a hyaluronic acid dermal filler by Revance and Teoxane, for moderate to severe undereye hollowing in adults 22 and older. A 52-week study found 93% of participants saw improvement at 3 months, with results lasting up to 12 months. Experts welcome the new option but caution that the trial wasn't large enough to rule out rare vascular complications.
The FDA has approved RHA Redensity Eye, a specialized hyaluronic acid (HA) dermal filler from Revance and Teoxane, for the correction of moderate to severe volume loss and hollowing under the eyes in adults aged 22 and older. It's only the second HA filler specifically cleared for the infraorbital (undereye) area, giving clinicians a new on-label option for one of the most technically demanding areas of the face to treat.
The approval was backed by a multicenter, randomized 52-week study showing that 93% of participants saw improvement at 3 months, with results lasting up to 12 months without touch-ups. The filler's formulation is designed to adapt to the delicate dynamics of the undereye region, and its safety profile showed no severe treatment-related adverse events during the study period.
Key Takeaways:
Why it matters: This approval broadens the toolkit for a highly requested aesthetic concern, but experts urge a measured read of the safety data — the trial was not designed to detect rare or delayed complications specific to this sensitive anatomic zone.
